Stay updated with breaking news from Inhibrx inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Inhibrx, Inc. (NASDAQ:INBX – Get Free Report) insider Brendan P. Eckelman sold 300,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $34.30, for a total value of $10,290,000.00. Following the sale, the insider now directly owns 1,735,553 shares of the company’s stock, […] ....
Sanofi: Sanofi completes acquisition of Inhibrx, Inc. finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Press Release: Sanofi completes acquisition of Inhibrx, Inc. finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
The global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is projected to reach USD 2,517 million by 2032, up from USD 1,413 million in 2022, growing at a CAGR of 6.1% during the forecast period from 2022 to 2032. This growth is driven by several key factors, including increasing awareness of AATD. ....